SCP
ABBV icon

Stamos Capital Partners’s AbbVie ABBV Stock Holding History

Stamos Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-20,750
Closed -$3.31M – 107
2023
Q1 		$3.31M Buy
20,750
+4,190
+25% +$641K 0.85% 27
2022
Q4 		$2.68M Buy
+16,560
New +$2.54M 0.85% 44

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Stamos Capital Partners's ABBV Position: Q2 2023 in Review

Stamos Capital Partners sold out of AbbVie (ABBV) in Q2 2023, closing a stake of 20,750 shares — an estimated $3.31M sold.

Stamos Capital Partners first reported a position in ABBV in Q4 2022 and held it in 2 quarters. The position peaked at $3.31M in Q1 2023. 3,076 funds tracked by Wall St. Rank hold ABBV as of Q2 2023.

  • Stamos Capital Partners reported no remaining AbbVie position as of Q2 2023 after selling out during the quarter.
  • Stamos Capital Partners sold 20,750 AbbVie shares in Q2 2023, an estimated $3.31M.
  • Stamos Capital Partners first reported a position in AbbVie in Q4 2022 and held it in 2 quarters.
  • Stamos Capital Partners's AbbVie position peaked at $3.31M in Q1 2023.
  • 3,076 funds tracked by Wall St. Rank held AbbVie as of Q2 2023.

Based on Stamos Capital Partners's 13F filing for Q2 2023, filed 11 Aug 2023.